We've had Eyes On the Datroway approval, and the associated removal of REMS requirements for CAR-T Therapeutics, along with a Biocon deal with Regeneron, and Bharat Biotech expansion plans for CGT manufacturing.

Just two weeks after our initial blogpost was published, 23andMe has made headlines again — this time for being acquired by Regeneron Pharmaceuticals in a deal valued at $256 million.

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.